SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Sold by Main Management LLC

Main Management LLC reduced its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 74.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 66,560 shares of the exchange traded fund’s stock after selling 189,620 shares during the quarter. SPDR S&P Biotech ETF comprises about 0.5% of Main Management LLC’s investment portfolio, making the stock its 29th biggest position. Main Management LLC’s holdings in SPDR S&P Biotech ETF were worth $6,576,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Bancorp lifted its stake in shares of SPDR S&P Biotech ETF by 3.4% in the 2nd quarter. Fifth Third Bancorp now owns 118,303 shares of the exchange traded fund’s stock valued at $10,968,000 after purchasing an additional 3,922 shares in the last quarter. PFG Investments LLC lifted its position in SPDR S&P Biotech ETF by 9.2% during the second quarter. PFG Investments LLC now owns 24,844 shares of the exchange traded fund’s stock valued at $2,303,000 after buying an additional 2,097 shares in the last quarter. IFG Advisory LLC purchased a new stake in SPDR S&P Biotech ETF during the second quarter worth approximately $241,000. Beaton Management Co. Inc. acquired a new stake in shares of SPDR S&P Biotech ETF in the third quarter worth $212,000. Finally, Atria Wealth Solutions Inc. increased its position in shares of SPDR S&P Biotech ETF by 56.1% in the second quarter. Atria Wealth Solutions Inc. now owns 16,597 shares of the exchange traded fund’s stock worth $1,539,000 after acquiring an additional 5,962 shares in the last quarter.

SPDR S&P Biotech ETF Trading Up 1.9 %

NYSEARCA:XBI opened at $99.14 on Friday. The firm’s fifty day simple moving average is $98.22 and its 200 day simple moving average is $96.84. SPDR S&P Biotech ETF has a twelve month low of $77.50 and a twelve month high of $105.47. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.